ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO1105

Association of the Insertion/Deletion Polymorphism of the ACE Gene with Acute Rejection and Chronic Dysfunction of Kidney Allografts

Session Information

  • Transplantation: Basic
    November 08, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Transplantation

  • 1901 Transplantation: Basic


  • Inzunza, Andres, Tecnológico de Monterrey, Guadalajara, Mexico
  • Topete reyes, Jorge fernando, Universidad de Guadalajara, Guadalajara, Mexico
  • Salazar-Paramo, Mario, Universidad de Guadalajara, Guadalajara, Mexico
  • Morán moguel, Maria cristina, Universidad de Guadalajara, Guadalajara, Mexico
  • López lozano, Carlos alberto, Universidad de Guadalajara, Guadalajara, Mexico
  • Pazarin-Villaseñor, Leonardo, Instituto Mexicano del Seguro Social, Guadalajara, Mexico
  • García Cárdenas, Mario Alberto, Universidad de Guadalajara, Guadalajara, Mexico
  • Parra Michel, Renato, Universidad de Guadalajara, Guadalajara, Mexico

There are several factors influencing the outcomes of kidney trasnplantion. It should be noted, that several individual genes are suspected to have a role in the clinical outcome of rejection. One of these candidates, is the insertion/deletion polymorphism, of the angiotensin converting enzyme (ACE) gene.


This work focuses on the role of the insertion/deletion polymorphism of ACE, in the clinical rejection of kidney allografts. We performed an analysis of 166 patients, and looked for a possible association between alleles and genotypes of (I/D) polymorphisms of the ACE gene,with episodes of acute rejection and CAN, in patients with kidney transplantation.


In the 166 patients included in the study, the genotype frequencies were heterogenous. We found that 35 patients (21%) were homozygous for the insertion genotype, 80 patients (48%) were heterozygous, and 51 patients (31%) had a homozygous genotype for deletion. Another statistical analysis was performed, in which the control group was considered independently from the four sub-groups of adverse events. We could observe statistically significant differences in the comparison amongst all of the groups (p 0.003) and in the analysis for the generalized additive models (I+ p <0.0001, D+ p 0.029).


No particular allele or genotype of the I/D polymorphism of the ACE can be associated with episodes of acute rejection, or with chronic allograft nephropathy, in patients with kidney allograft transplant. We can also conclude that the Homozygous Deletion allele of the I/D polymorphism, can be associated with toxicity by calcineurin inhibitors, at least in the population studied in this present work.